The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting a Phospholipid Unique to Mitochondrial Membranes as a Therapeutic for Parkinson’s Disease
Study Rationale: Mitochondria are energy-generating structures vital to the health of all cells. In Parkinson’s disease (PD), mitochondrial dysfunction leads to neuronal degeneration and to the motor...
-
LRRK2, 2011fMRI of First Degree Relatives of LRRK2 Positive Parkinson's Disease Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in PD patients who recently converted into a diseased state by comparing... -
Research Grant, 2018Searching Brain Scan Data for Patterns of Activity Associated with Parkinson's Disease
Study Rationale:
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease... -
Rapid Response Innovation Awards, 2011Alpha-synuclein and Tau Mislocalization to Dendritic Spines
Objective/Rationale:
In addition to motor disorders, Parkinson disease (PD) patients also suffer from cognitive deficits, which are believed to result from abnormal accumulation of alpha-synuclein, a... -
Therapeutic Pipeline Program, 2015Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach
Study Rationale:
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)... -
Repositioning Drugs for PD, 2011Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.